Teladoc Inc (NYSE:TDOC) insider Lewis Levy sold 1,284 shares of the firm’s stock in a transaction dated Monday, September 17th. The shares were sold at an average price of $77.00, for a total value of $98,868.00. Following the sale, the insider now owns 1,284 shares of the company’s stock, valued at $98,868. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Lewis Levy also recently made the following trade(s):
- On Wednesday, August 15th, Lewis Levy sold 1,285 shares of Teladoc stock. The shares were sold at an average price of $70.80, for a total value of $90,978.00.
- On Monday, July 16th, Lewis Levy sold 22,768 shares of Teladoc stock. The shares were sold at an average price of $65.77, for a total value of $1,497,451.36.
Shares of TDOC stock opened at $75.45 on Thursday. The company has a debt-to-equity ratio of 0.58, a quick ratio of 3.14 and a current ratio of 3.14. Teladoc Inc has a one year low of $27.30 and a one year high of $79.64.
Several hedge funds have recently modified their holdings of TDOC. We Are One Seven LLC lifted its position in shares of Teladoc by 241.1% during the first quarter. We Are One Seven LLC now owns 2,845 shares of the health services provider’s stock worth $115,000 after purchasing an additional 2,011 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Teladoc by 68.8% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,874 shares of the health services provider’s stock worth $116,000 after purchasing an additional 1,171 shares during the last quarter. Rockefeller Capital Management L.P. bought a new position in shares of Teladoc during the first quarter worth about $154,000. Garner Asset Management Corp bought a new position in Teladoc in the second quarter worth about $200,000. Finally, Pier 88 Investment Partners LLC bought a new position in Teladoc in the second quarter worth about $201,000.
Several analysts have recently weighed in on TDOC shares. KeyCorp raised their target price on Teladoc from $74.00 to $90.00 and gave the company an “overweight” rating in a research note on Monday, August 27th. Berenberg Bank started coverage on Teladoc in a research note on Monday, July 9th. They set a “buy” rating and a $72.00 target price for the company. Jefferies Financial Group set a $74.00 target price on Teladoc and gave the company a “buy” rating in a research note on Wednesday, July 11th. Leerink Swann started coverage on Teladoc in a research note on Thursday, August 16th. They set an “outperform” rating and a $90.00 target price for the company. Finally, Wells Fargo & Co restated a “buy” rating and set a $70.00 target price on shares of Teladoc in a research note on Thursday, August 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $65.10.
Teladoc Company Profile
Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.